Skip to content
value.today

Codexis, Inc.: peers

Change the peers

Codexis, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Codexis, Inc., Perspective Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Compass Therapeutics, Inc., TuHURA Biosciences, Inc. NV, Voyager Therapeutics, Inc., Armata Pharmaceuticals, Inc., Spruce Biosciences, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCodexis, Inc.base
CDXS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Perspective Therapeutics, Inc.
CATX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Inovio Pharmaceuticals, Inc.
INO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Compass Therapeutics, Inc.
CMPX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
TuHURA Biosciences, Inc. NV
HURA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Voyager Therapeutics, Inc.
VYGR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Armata Pharmaceuticals, Inc.
ARMP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Spruce Biosciences, Inc.
SPRB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$140 MOct 26, 2026 · Market data3rd of 8$141 MOct 30, 2026 · Market data2nd of 8$144 MOct 30, 2026 · Market data1st of 8$137 MOct 29, 2026 · Market data4th of 8$135 MOct 30, 2026 · Market data5th of 8$134 MOct 14, 2026 · Market data6th of 8$130 MOct 28, 2026 · Market data7th of 8$130 MOct 26, 2026 · Market data8th of 8$136 M8 ranked
Revenue (Better neither way: ranked highest first)$70 MFY2025 · SEC1st of 3——$0 MFY2025 · SEC3rd of 3————$40 MFY2025 · SEC2nd of 3————$40 M3 ranked
Net income (Higher is better)$-44 MFY2025 · SEC3rd of 8$-103 MFY2025 · SEC6th of 8$-85 MFY2025 · SEC5th of 8$-66 MFY2025 · SEC4th of 8$-30 MFY2025 · SEC1st of 8$-120 MFY2025 · SEC7th of 8$-174 MFY2025 · SEC8th of 8$-39 MFY2025 · SEC2nd of 8$-76 M8 ranked
Employees (Better neither way: ranked highest first)261As on 2021 · Profile2nd of 6——317As on 2021 · Profile1st of 639December 31, 2025 · Profile5th of 622December 31, 2025 · Profile6th of 6141December 31, 2025 · Profile3rd of 661March 18, 2026 · Profile4th of 6——1016 ranked
Growth
Revenue growth (Higher is better)+18.6%FY2025 · SEC1st of 266th77th————————————————-49.5%FY2025 · SEC2nd of 24th1st————————-15.5%2 ranked
Revenue growth, 3 years a year (Higher is better)-20.2%FY2025 · SEC2nd of 26th4th————————————————-0.4%FY2025 · SEC1st of 226th31st————————-10.3%2 ranked
Margins and returns
Gross margin (Higher is better)86.7%FY2025 · SEConly one with it88th95th————————————————————————————86.7%—
Operating margin (Higher is better)-59.3%FY2025 · SEC1st of 229th14th————————————————-326.6%FY2025 · SEC2nd of 211th3rd————————-192.9%2 ranked
Net margin (Higher is better)-62.5%FY2025 · SEC1st of 228th13th————————————————-296.6%FY2025 · SEC2nd of 211th4th————————-179.5%2 ranked
Free cash flow margin (Higher is better)-33.9%FY2025 · SEC1st of 231st14th————————————————-334.6%FY2025 · SEC2nd of 211th3rd————————-184.2%2 ranked
Return on equity (Higher is better)-74.9%FY2025 · SEC4th of 732nd13th-41.4%FY2025 · SEC2nd of 748th20th-183.5%FY2025 · SEC7th of 712th5th-41.3%FY2025 · SEC1st of 748th20th-169.2%FY2025 · SEC6th of 713th6th-48.3%FY2025 · SEC3rd of 744th19th————-109.3%FY2025 · SEC5th of 722nd10th-74.9%7 ranked
Valuation
Price to sales (Better neither way: ranked highest first)1.6×price Oct 26, 2026 · Market data2nd of 227th41st————————————————5.3×price Oct 14, 2026 · Market data1st of 258th79th————————3.5×2 ranked
Price to book (Better neither way: ranked highest first)2.8×price Oct 26, 2026 · Market data4th of 747th59th0.7×price Oct 30, 2026 · Market data6th of 712th11th6.0×price Oct 30, 2026 · Market data2nd of 772nd80th0.7×price Oct 29, 2026 · Market data5th of 712th12th6.5×price Oct 30, 2026 · Market data1st of 774th82nd0.7×price Oct 14, 2026 · Market data6th of 712th11th————3.0×price Oct 26, 2026 · Market data3rd of 749th62nd2.8×7 ranked
Free cash flow yield (Higher is better)-17.0%price Oct 26, 2026 · Market data1st of 835th16th-67.4%price Oct 30, 2026 · Market data7th of 813th5th-61.6%price Oct 30, 2026 · Market data6th of 815th6th-35.9%price Oct 29, 2026 · Market data4th of 823rd10th-20.5%price Oct 30, 2026 · Market data3rd of 832nd14th-101.0%price Oct 14, 2026 · Market data8th of 87th3rd-20.3%price Oct 28, 2026 · Market data2nd of 833rd15th-43.1%price Oct 26, 2026 · Market data5th of 820th9th-39.5%8 ranked
Financial strength
Debt to equity (Lower is better)0.8×FY2025 · SEC3rd of 369th60th0.0×FY2025 · SEC2nd of 310th7th————————————————————0.0×FY2025 · SEC1st of 35th3rd0.0×3 ranked
Interest cover (Higher is better)————————————————————————————-405.7×FY2025 · SEConly one with it7th2nd-405.7×—
Piotroski F-score (Higher is better)4 of 9FY2025 · SEConly one with it——————————————4.0 of 9—
Scorecard
Scorecard (Higher is better)7 of 22FY2025 · Scorecard1st of 84 of 14FY2025 · Scorecard2nd of 82 of 13FY2025 · Scorecard7th of 82 of 10FY2025 · Scorecard3rd of 80 of 12FY2025 · Scorecard8th of 84 of 20FY2025 · Scorecard3rd of 82 of 11FY2025 · Scorecard6th of 83 of 15FY2025 · Scorecard3rd of 820% passed8 ranked
Valuation checks (Higher is better)2 of 5FY2025 · Scorecard1st of 81 of 4FY2025 · Scorecard3rd of 80 of 4FY2025 · Scorecard5th of 81 of 4FY2025 · Scorecard3rd of 80 of 4FY2025 · Scorecard5th of 82 of 5FY2025 · Scorecard1st of 80 of 4FY2025 · Scorecard5th of 80 of 4FY2025 · Scorecard5th of 813% passed8 ranked
Growth checks (Higher is better)1 of 6FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard3rd of 80 of 6FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard3rd of 80% passed8 ranked
Profitability checks (Higher is better)1 of 5FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80 of 5FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80% passed8 ranked
Financial health checks (Higher is better)3 of 5FY2025 · Scorecard2nd of 83 of 4FY2025 · Scorecard1st of 81 of 3FY2025 · Scorecard6th of 81 of 2FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard8th of 81 of 3FY2025 · Scorecard6th of 81 of 2FY2025 · Scorecard4th of 83 of 5FY2025 · Scorecard2nd of 850% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 7——0 of 1FY2025 · Scorecard3rd of 71 of 1FY2025 · Scorecard1st of 71 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard3rd of 70% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)68.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 866.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 833.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 889.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 810.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 858.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 815.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 867.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 862.1%8 ranked
Institutions holding (Better neither way: ranked highest first)1302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 81182026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 81112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 81722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 81212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8642026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 81158 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-8.3 pp2026-Q2 against 2026-Q1 · 13F7th of 8+4.0 pp2026-Q2 against 2026-Q1 · 13F2nd of 8-13.7 pp2026-Q2 against 2026-Q1 · 13F8th of 8-4.2 pp2026-Q2 against 2026-Q1 · 13F6th of 8-0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 8+0.6 pp2026-Q2 against 2026-Q1 · 13F4th of 8+2.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+15.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8-0.1 pp8 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Codexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Perspective Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inovio Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Compass Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; TuHURA Biosciences, Inc. NV: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Voyager Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Armata Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Spruce Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Codexis, Inc.-59.3%FY2025
29th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies
Perspective Therapeutics, Inc.———
Inovio Pharmaceuticals, Inc.———
Compass Therapeutics, Inc.———
TuHURA Biosciences, Inc. NV———
Voyager Therapeutics, Inc.-326.6%FY2025
11th percentile in Healthcaremedian -7.7%, 674 companies
3rd percentile in USAmedian 3.5%, 2,594 companies
Armata Pharmaceuticals, Inc.———
Spruce Biosciences, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$63 M$125 M$188 M$250 M20102012201420162018202020222024Codexis, Inc. $70 MPerspective Therapeutics, Inc. $1 MInovio Pharmaceuticals, Inc. $0 MVoyager Therapeutics, Inc. $40 MArmata Pharmaceuticals, Inc. $0 MSpruce Biosciences, Inc. $5 M

Rank in the group

1st2nd3rd4th5th201120122013201420152016201720182019202020212022202320242025Codexis, Inc.: 1st of 3 in 2011Codexis, Inc.: 1st of 3 in 2012Codexis, Inc.: 1st of 4 in 2013Codexis, Inc.: 1st of 4 in 2014Codexis, Inc.: 1st of 4 in 2015Codexis, Inc.: 1st of 4 in 2016Codexis, Inc.: 1st of 4 in 2017Codexis, Inc.: 1st of 4 in 2018Codexis, Inc.: 2nd of 4 in 2019Codexis, Inc.: 2nd of 4 in 2020Codexis, Inc.: 1st of 3 in 2021Codexis, Inc.: 1st of 3 in 2022Codexis, Inc.: 2nd of 5 in 2023Codexis, Inc.: 2nd of 5 in 2024Codexis, Inc.: 1st of 3 in 2025Codexis, Inc.Perspective Therapeutics, Inc.: 3rd of 3 in 2011Perspective Therapeutics, Inc.: 2nd of 3 in 2012Perspective Therapeutics, Inc.: 3rd of 4 in 2013Perspective Therapeutics, Inc.: 3rd of 4 in 2014Perspective Therapeutics, Inc.: 4th of 4 in 2015Perspective Therapeutics, Inc.: 4th of 4 in 2016Perspective Therapeutics, Inc.: 4th of 4 in 2017Perspective Therapeutics, Inc.: 4th of 4 in 2018Perspective Therapeutics, Inc.: 3rd of 4 in 2019Perspective Therapeutics, Inc.: 3rd of 4 in 2020Perspective Therapeutics, Inc.: 3rd of 3 in 2021Perspective Therapeutics, Inc.: 4th of 5 in 2023Perspective Therapeutics, Inovio Pharmaceuticals, Inc.: 2nd of 3 in 2011Inovio Pharmaceuticals, Inc.: 3rd of 3 in 2012Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2013Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2014Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2015Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2016Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2017Inovio Pharmaceuticals, Inc.: 2nd of 4 in 2018Inovio Pharmaceuticals, Inc.: 4th of 4 in 2019Inovio Pharmaceuticals, Inc.: 4th of 4 in 2020Inovio Pharmaceuticals, Inc.: 3rd of 3 in 2022Inovio Pharmaceuticals, Inc.: 5th of 5 in 2023Inovio Pharmaceuticals, Inc.: 5th of 5 in 2024Inovio Pharmaceuticals, Inc.: 3rd of 3 in 2025Inovio Pharmaceuticals, InCompass Therapeutics, Inc.: 4th of 5 in 2024Compass Therapeutics, Inc.Voyager Therapeutics, Inc.: 3rd of 4 in 2015Voyager Therapeutics, Inc.: 3rd of 4 in 2016Voyager Therapeutics, Inc.: 3rd of 4 in 2017Voyager Therapeutics, Inc.: 3rd of 4 in 2018Voyager Therapeutics, Inc.: 1st of 4 in 2019Voyager Therapeutics, Inc.: 1st of 4 in 2020Voyager Therapeutics, Inc.: 2nd of 3 in 2021Voyager Therapeutics, Inc.: 2nd of 3 in 2022Voyager Therapeutics, Inc.: 1st of 5 in 2023Voyager Therapeutics, Inc.: 1st of 5 in 2024Voyager Therapeutics, Inc.: 2nd of 3 in 2025Voyager Therapeutics, Inc.Armata Pharmaceuticals, Inc.: 4th of 4 in 2013Armata Pharmaceuticals, Inc.: 4th of 4 in 2014Armata Pharmaceuticals, InSpruce Biosciences, Inc.: 3rd of 5 in 2023Spruce Biosciences, Inc.: 3rd of 5 in 2024Spruce Biosciences, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCodexis, Inc.Perspective Therapeutics, Inc.Inovio Pharmaceuticals, Inc.Compass Therapeutics, Inc.TuHURA Biosciences, Inc. NVVoyager Therapeutics, Inc.Armata Pharmaceuticals, Inc.Spruce Biosciences, Inc.
2025$70 MSEC1st—$0 MSEC3rd——$40 MSEC2nd——
2024$59 MSEC2nd—$0 MSEC5th$1 MSEC4th—$80 MSEC1st—$5 MSEC3rd
2023$70 MSEC2nd$1 MSEC4th$1 MSEC5th——$250 MSEC1st—$10 MSEC3rd
2022$139 MSEC1st—$10 MSEC3rd——$41 MSEC2nd——
2021$105 MSEC1st$10 MSEC3rd———$37 MSEC2nd——
2020$69 MSEC2nd$10 MSEC3rd$7 MSEC4th——$171 MSEC1st——
2019$68 MSEC2nd$7 MSEC3rd$4 MSEC4th——$104 MSEC1st——
2018$61 MSEC1st$6 MSEC4th$30 MSEC2nd——$8 MSEC3rd——
2017$50 MSEC1st$5 MSEC4th$42 MSEC2nd——$10 MSEC3rd——
2016$49 MSEC1st$5 MSEC4th$35 MSEC2nd——$14 MSEC3rd——
2015$42 MSEC1st$5 MSEC4th$41 MSEC2nd——$17 MSEC3rd——
2014$35 MSEC1st$4 MSEC3rd$10 MSEC2nd———$0 MSEC4th—

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Codexis, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Perspective Therapeutics, Inc.CATX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $141 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $141 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $144 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Compass Therapeutics, Inc.CMPX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $137 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $137 M (Oct 29, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • TuHURA Biosciences, Inc. NVHURA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $135 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $135 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Voyager Therapeutics, Inc.VYGR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $134 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $134 M (Oct 14, 2026) · revenue $40 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Armata Pharmaceuticals, Inc.ARMP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $130 M (Oct 28, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Spruce Biosciences, Inc.SPRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $130 M (Oct 26, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Sutro Biopharma, Inc.STRO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $155 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $155 M (Oct 26, 2026) · revenue $102 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Nkarta, Inc.NKTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125 M (Oct 22, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Humacyte, Inc.HUMA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125 M (Oct 28, 2026) · revenue $2 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Anavex Life Sciences Corp.AVXL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $123 M (Oct 26, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Foghorn Therapeutics Inc.FHTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.